Treatment of Inflammatory Bowel Disease
From: Klinik und Poliklinik für Innere Medizin I, Klinikum der Universität Regensburg. juergen.schoelmerich@klinik.uni-r.de
Schweizerische Rundschau für Medizin Praxis = Revue suisse de médecine Praxis
- Publish Date: Feb 2007
- ISSN: 1013-2058
- Volume: 96
- Issue: 9
- Pages: 337-43
- Medium: Print
- Language:
- Citation (JAMA): Schölmerich J, et al. Treatment of Inflammatory Bowel Disease. Schweiz. Rundsch. Med. Prax. Feb 2007;96:337-43
Abstract
Standard treatment for IBD with 5-ASA, steroids and immunosuppressants is rather effective and currently optimized using combinations of drugs or application routes. Among the biologics only infliximab has reached the therapeutic arsenal for Crohn’s disease — it is as well effective in some patients with ulcerative colitis. Early aggressive treatment thus far is not established. Hormones and growth factors may play a role. Probiotics have a place in the treatment in particular for ulcerative colitis.
Mesh Headings (Keywords): Anti-Inflammatory Agents, Biological Products, Colitis, Ulcerative, Crohn Disease, Humans, Mesalamine, Prednisolone, Probiotics
Check for Full Text / PubMed Unique Identifier (PMID): 17361635
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.